Welcome to our dedicated page for Nuvalent SEC filings (Ticker: NUVL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Nuvalent, Inc. (NUVL) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Nuvalent is a clinical-stage biopharmaceutical company listed on The Nasdaq Global Select Market, and its filings offer detailed information on clinical progress, financing activities, and key business agreements related to its targeted oncology pipeline.
Recent Form 8-K filings describe pivotal and preliminary data for neladalkib in ALK-positive NSCLC from the ALKOVE-1 Phase 1/2 trial, pivotal data for zidesamtinib in ROS1-positive NSCLC from the ARROS-1 Phase 1/2 trial, and the initiation of the ALKAZAR Phase 3 trial in TKI-naïve ALK-positive NSCLC. Other 8-Ks outline the completion and FDA acceptance of a New Drug Application for zidesamtinib in TKI pre-treated ROS1-positive NSCLC, plans for an NDA submission for neladalkib, and the assignment of a PDUFA target action date for zidesamtinib.
Filings also document Nuvalent’s capital markets activity, including an underwriting agreement for a public offering of Class A common stock under an automatically effective shelf registration statement on Form S-3, and the company’s estimate that proceeds from the offering, together with existing cash, cash equivalents, and marketable securities, would fund operations into 2029. Additional disclosures cover a preexisting royalty interest on future net sales of neladalkib and zidesamtinib, as well as periodic 8-Ks furnishing quarterly financial results press releases.
On Stock Titan, these SEC filings are paired with AI-powered summaries that highlight the main points of each document, helping readers quickly understand clinical data updates, NDA milestones, financing terms, and other material events. Users can review 10-K and 10-Q reports, 8-K current reports, registration statements, and exhibits, and use the AI-generated insights to navigate lengthy technical and legal language more efficiently while researching NUVL.
Nuvalent (NUVL) reported insider activity by its Chief Scientific Officer. On 10/15/2025, the officer exercised stock options for 3,668 shares at $18.93, 7,495 shares at $27.85, and 3,042 shares at $72.35, then sold 14,205 Class A shares at a weighted average price of $90.04 (range $89.84–$90.23).
The transactions were made under a Rule 10b5-1 trading plan adopted on November 1, 2024. Following these trades, the officer directly beneficially owned 65,963 Class A shares.
Nuvalent (NUVL) reported an insider transaction by its Chief Financial Officer. On 10/15/2025, the CFO exercised 1,683 stock options at $18.93 per share and sold 1,683 Class A shares at a weighted average price of $85.57, with individual sales ranging from $85.00 to $85.69. The trades were made under a Rule 10b5-1 plan adopted on December 12, 2024.
Following these transactions, the CFO beneficially owned 61,734 Class A shares directly and 28,979 derivative securities (stock options). The filing lists transaction codes M (option exercise) and S (sale).
Nuvalent (NUVL) insider activity: The Chief Scientific Officer reported option exercises and open‑market sales on 10/13/2025 and 10/14/2025 under a Rule 10b5-1 trading plan adopted on November 1, 2024.
Exercises included Class A Common Stock options for 1,669 at $18.93, 4,168 at $27.85, and 1,800 at $72.35 on 10/13, and 731 at $18.93, 877 at $27.85, and 825 at $29.33 on 10/14. Sales included 7,637 at a weighted average price of $89.81 on 10/13 (range $89.80–$89.83), and on 10/14: 1,167 at $84.98 (range $84.64–$85.63), 866 at $86.11 (range $85.89–$86.81), and 400 at $87.39 (range $87.33–$87.56).
Following the reported transactions, the reporting person beneficially owned 65,963 Class A Common Stock shares directly.
Nuvalent (NUVL) reported insider transactions by its Chief Financial Officer. On 10/13/2025 and 10/14/2025, the CFO exercised employee stock options and sold shares pursuant to a Rule 10b5-1 trading plan adopted on December 12, 2024.
On 10/13, options for 6,875 shares at $6.89 and 13,125 shares at $18.93 were exercised, followed by sales totaling 20,000 shares at weighted-average prices within disclosed ranges of $87.15–$89.28. On 10/14, 20,000 options at $18.93 were exercised and 20,000 shares were sold at weighted-average prices within $85.17–$89.12. Following these transactions, the CFO beneficially owned 61,734 Class A shares directly and 30,662 options remained outstanding.
Alexandra Balcom, Chief Financial Officer of Nuvalent, Inc. (NUVL), reported multiple transactions on 10/01/2025 under a Rule 10b5-1 trading plan adopted on 12/12/2024. The filing shows purchases (option exercises) totaling 20,000 shares acquired at exercise prices of $6.89 and $18.93, and open stock option holdings of 20,000 underlying shares exercisable through 2031 and 2032. Balcom sold 20,000 Class A shares in two weighted-average-price blocks: 19,030 shares at an average of $85.43 and 970 shares at an average of $86.37, leaving 61,734 Class A shares beneficially owned after the transactions. The filing was signed by an attorney-in-fact on 10/03/2025.
Alexandra Balcom, Chief Financial Officer of Nuvalent, Inc. (NUVL), reported option exercises and sales on September 29-30, 2025. She acquired 7,588 shares on 09/29/2025 and 20,000 shares on 09/30/2025 by exercising stock options with an exercise price of $6.89 per share. Those exercises increased the number of shares underlying her options as reported in Table II to 79,638 and then to 59,638 following the reported activity.
Concurrently, Balcom sold the same numbers of Class A common shares: 7,588 shares on 09/29/2025 at a weighted average price of $85.01 (sales ranged $85.00–$85.05) and 20,000 shares on 09/30/2025 at a weighted average price reported at $85.06 (sales ranged $85.00–$85.37). After these transactions, the Form 4 shows 61,734 shares of Class A common stock beneficially owned.
Nuvalent insider transactions on 09/29/2025: Darlene Noci, Chief Development Officer, executed transactions under a Rule 10b5-1 plan adopted on November 18, 2024. She exercised a stock option to acquire 4,000 shares at an exercise price of $27.85 and contemporaneously sold 4,000 Class A common shares in multiple block sales at weighted average prices ranging from $81.39 to $84.92 across several lots.
Following these transactions the Form 4 reports 48,034 shares of Class A common stock beneficially owned and 4,000 shares subject to the option exercised, with the filing also showing 126,329 derivative securities beneficially owned following the reported transactions. The reporting attorney-in-fact signed the form on 10/01/2025.
Nuvalent, Inc. (NUVL) insider filing reports a proposed sale of 12,000 Class A Common shares through J.P. Morgan Securities on NASDAQ with an aggregate market value of $975,600. The shares were acquired and are to be sold on 09/29/2025 following a stock option exercise, with payment in cash. The filing identifies the selling person as Darlene Noci, who sold 4,000 shares on 07/30/2025 for $321,460 and 4,000 shares on 08/25/2025 for $298,494 during the prior three months. The filing also discloses 66,669,583 shares outstanding. No additional narrative, relationship to issuer, or trading-plan dates are provided in the notice.
Nuvalent, Inc. (ticker: NUVL) filed a Form 144 reporting a proposed sale of 60,000 shares of Class A common stock through J.P. Morgan Securities LLC on NASDAQ, with an aggregate market value of $4,878,000 and an approximate sale date of 09/29/2025. The securities were acquired on 09/29/2025 through a stock option exercise and paid for in cash. The filing discloses two prior small sales by the same person in July 2025 totaling 20,000 shares for gross proceeds of $1,695,473. The filer certifies no undisclosed material adverse information.
Nuvalent, Inc. filed a current report describing a key regulatory milestone for its lead oncology program. On September 22, 2025, the company completed submission of a New Drug Application to the U.S. Food and Drug Administration for zidesamtinib as a treatment for tyrosine kinase inhibitor pre-treated patients with advanced ROS1-positive non-small cell lung cancer. This step means Nuvalent has finished providing the clinical and other data the agency needs to begin its formal review of the drug candidate for this specific patient group.